{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:50:06Z","timestamp":1792093806365,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52130301"],"award-info":[{"award-number":["52130301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52522306"],"award-info":[{"award-number":["52522306"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32271444"],"award-info":[{"award-number":["32271444"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Science Bulletin"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.scib.2026.08.080","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:36:53Z","timestamp":1788190613000},"page":"5045-5057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Activation-optimized anti-CD3 valency control enables combinatorial discovery of multi-specific nanoantibodies for solid tumor immunotherapy"],"prefix":"10.1016","volume":"71","author":[{"given":"Long","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Kang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Hai","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Kun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Ru","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.scib.2026.08.080_b0005","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.scib.2026.08.080_b0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/d41573-022-00040-2","article-title":"Bispecific antibodies in oncology","volume":"21","author":"Esfandiari","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.scib.2026.08.080_b0015","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.cell.2023.06.020","article-title":"Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy","volume":"186","author":"Dolton","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.scib.2026.08.080_b0020","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.scib.2026.08.080_b0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nri1000","article-title":"CD3-specific antibody-induced active tolerance: from bench to bedside","volume":"3","author":"Chatenoud","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.scib.2026.08.080_b0030","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.scib.2026.08.080_b0035","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/imm.12809","article-title":"Selected signalling proteins recruited to the T-cell receptor-CD3 complex","volume":"153","author":"Ngoenkam","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.scib.2026.08.080_b0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax8861","article-title":"CD3 bispecific antibody\u2013induced cytokine release is dispensable for cytotoxic T cell activity","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.scib.2026.08.080_b0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41577-025-01221-x","article-title":"Regulators of CD8+ T cell exhaustion","volume":"26","author":"Sun","year":"2026","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.scib.2026.08.080_b0050","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.scib.2026.08.080_b0055","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T cell engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.scib.2026.08.080_b0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.scib.2026.08.080_b0065","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.scib.2026.08.080_b0070","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/cancers15041189","article-title":"Modulating T cell responses by targeting CD3","volume":"15","author":"Menon","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.scib.2026.08.080_b0075","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1871171","article-title":"One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics","volume":"13","author":"Chen","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.scib.2026.08.080_b0080","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2584374","article-title":"Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs","volume":"17","author":"Abdelmotaleb","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.scib.2026.08.080_b0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.scib.2026.08.080_b0090","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133757","article-title":"Target arm affinities determine preclinical efficacy and safety of anti-HER2\/CD3 bispecific antibody","volume":"5","author":"Staflin","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.scib.2026.08.080_b0095","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.scib.2026.08.080_b0100","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"De Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.scib.2026.08.080_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.medp.2023.100002","article-title":"Targeting immunogenic cell death for cancer immunotherapy","volume":"1","author":"Zhang","year":"2024","journal-title":"Med Plus"},{"key":"10.1016\/j.scib.2026.08.080_b0110","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","article-title":"Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors","volume":"4","author":"Cattaruzza","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.scib.2026.08.080_b0115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2159-8290.CD-23-0984","article-title":"AMG 509 (xaluritamig), an anti-STEAP1 XmAb 2+ 1 T-cell redirecting immune therapy with avidity-dependent activity against prostate cancer","volume":"14","author":"Nolan-Stevaux","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.scib.2026.08.080_b0120","doi-asserted-by":"crossref","first-page":"14397","DOI":"10.1038\/s41598-021-93842-0","article-title":"Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning","volume":"11","author":"Haber","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.scib.2026.08.080_b0125","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/cancers13020287","article-title":"Overcoming challenges for CD3-bispecific antibody therapy in solid tumors","volume":"13","author":"Middelburg","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.scib.2026.08.080_b0130","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk1894","article-title":"Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data","volume":"10","author":"Rubahamya","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.scib.2026.08.080_b0135","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1182\/blood-2022-163235","article-title":"Pharmacodynamics and biomarker correlates of imvotamab (IGM-2323), the first-in-class CD20\u00d7 CD3 bispecific IgM antibody with dual mechanisms of action, in patients with advanced B cell malignancies","volume":"140","author":"Hernandez","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.scib.2026.08.080_b0140","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2026.08.080_b0145","first-page":"37","article-title":"Next generation of multispecific antibody engineering","volume":"7","author":"Keri","year":"2024","journal-title":"Antib Ther"},{"key":"10.1016\/j.scib.2026.08.080_b0150","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","article-title":"Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases","volume":"21","author":"Rolin","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.scib.2026.08.080_b0155","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.scib.2026.08.080_b0160","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41551-025-01569-4","article-title":"A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity","volume":"10","author":"Yang","year":"2026","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.scib.2026.08.080_b0165","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/s41551-024-01214-6","article-title":"Antibody-displaying extracellular vesicles for targeted cancer therapy","volume":"8","author":"Wiklander","year":"2024","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.scib.2026.08.080_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.medp.2025.100087","article-title":"Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives","volume":"2","author":"Miao","year":"2025","journal-title":"Medicine Plus"},{"key":"10.1016\/j.scib.2026.08.080_b0175","series-title":"Successful Drug Discovery","first-page":"221","article-title":"Discovery and development of emicizumab (Hemlibra\u00ae): a humanized bispecific antibody to coagulation factors IXa and X with a factor VIII cofactor activity","author":"Kitazawa","year":"2021"},{"key":"10.1016\/j.scib.2026.08.080_b0180","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.scib.2026.08.080_b0185","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s43018-022-00359-0","article-title":"Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR\u00d7 LGR5 bispecific antibody with efficacy in epithelial tumors","volume":"3","author":"Herpers","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.scib.2026.08.080_b0190","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2394229","article-title":"Developability considerations for bispecific and multispecific antibodies","volume":"16","author":"Amash","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.scib.2026.08.080_b0195","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/s41590-022-01288-x","article-title":"Kinetic proofreading through the multi-step activation of the ZAP70 kinase underlies early T cell ligand discrimination","volume":"23","author":"Voisinne","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.scib.2026.08.080_b0200","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nri3728","article-title":"Phenotypic models of T cell activation","volume":"14","author":"Lever","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.scib.2026.08.080_b0205","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj4632","article-title":"TCR\/CD3-based synthetic antigen receptors (TCC) convey superior antigen sensitivity combined with high fidelity of activation","volume":"10","author":"M\u00fchlgrabner","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.scib.2026.08.080_b0210","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1021\/acsnano.4c08293","article-title":"Tuning surface valences of nanoengagers to enhance their structural advantages for efficiently redirecting T cells against solid tumors","volume":"19","author":"Huang","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.scib.2026.08.080_b0215","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41551-025-01425-5","article-title":"Engineering multi-specific nano-antibodies for cancer immunotherapy","volume":"9","author":"Fan","year":"2025","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.scib.2026.08.080_b0220","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nri1632","article-title":"NFAT proteins: key regulators of T cell development and function","volume":"5","author":"Macian","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.scib.2026.08.080_b0225","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","article-title":"The transcription factor NFAT promotes exhaustion of activated CD8+ T cells","volume":"42","author":"Martinez","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.scib.2026.08.080_b0230","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.scib.2026.08.080_b0235","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","article-title":"LAG3 associates with TCR\u2013CD3 complexes and suppresses signaling by driving co-receptor\u2013lck dissociation","volume":"23","author":"Guy","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.scib.2026.08.080_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2021.105955","article-title":"IgG-like bispecific antibody platforms with built-in purification-facilitating elements","volume":"188","author":"Li","year":"2021","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.scib.2026.08.080_b0245","first-page":"73","article-title":"Current trends and challenges in the downstream purification of bispecific antibodies","volume":"4","author":"Chen","year":"2021","journal-title":"Antib Ther"},{"key":"10.1016\/j.scib.2026.08.080_b0250","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41467-021-21497-6","article-title":"Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy","volume":"12","author":"Jiang","year":"2021","journal-title":"Nat Commun"}],"container-title":["Science Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927326010017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927326010017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:30:34Z","timestamp":1792092634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095927326010017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2095927326010017"],"URL":"https:\/\/doi.org\/10.1016\/j.scib.2026.08.080","relation":{},"ISSN":["2095-9273"],"issn-type":[{"value":"2095-9273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation-optimized anti-CD3 valency control enables combinatorial discovery of multi-specific nanoantibodies for solid tumor immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Science Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scib.2026.08.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Science China Press. Published by Elsevier B.V. and Science China Press. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}